Cargando…
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
BACKGROUND: There is limited evidence that rituximab, a B cell depletion therapy, is an effective treatment for systemic lupus erythematosus (SLE). Data on the mechanisms of B cell depletion in SLE indicate that the combination of rituximab and belimumab may be more effective than rituximab alone. T...
Autores principales: | Muller, Patrick, Chowdhury, Kashfia, Gordon, Caroline, Ehrenstein, Michael R., Doré, Caroline J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364494/ https://www.ncbi.nlm.nih.gov/pubmed/32677992 http://dx.doi.org/10.1186/s13063-020-04391-2 |
Ejemplares similares
-
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
por: Jones, Alexis, et al.
Publicado: (2019) -
Corneal cross-linking versus standard care in children with keratoconus – a randomised, multicentre, observer-masked trial of efficacy and safety (KERALINK): a statistical analysis plan
por: Chowdhury, Kashfia, et al.
Publicado: (2020) -
A randomised, multi-centre trial of total ankle replacement versus ankle arthrodesis in the treatment of patients with end stage ankle osteoarthritis (TARVA): statistical analysis plan
por: Muller, Patrick, et al.
Publicado: (2020) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)